Inmune Bio (INMB) EBIAT (2018 - 2025)
Inmune Bio's EBIAT history spans 8 years, with the latest figure at -$6.5 million for Q3 2025.
- For Q3 2025, EBIAT rose 46.51% year-over-year to -$6.5 million; the TTM value through Sep 2025 reached -$49.9 million, down 20.87%, while the annual FY2024 figure was -$42.1 million, 40.24% down from the prior year.
- EBIAT for Q3 2025 was -$6.5 million at Inmune Bio, up from -$24.5 million in the prior quarter.
- Across five years, EBIAT topped out at -$4.6 million in Q1 2021 and bottomed at -$24.5 million in Q2 2025.
- The 5-year median for EBIAT is -$8.4 million (2023), against an average of -$9.0 million.
- The largest annual shift saw EBIAT crashed 215.7% in 2021 before it soared 46.51% in 2025.
- A 5-year view of EBIAT shows it stood at -$9.7 million in 2021, then surged by 39.69% to -$5.8 million in 2022, then plummeted by 44.15% to -$8.4 million in 2023, then fell by 9.63% to -$9.2 million in 2024, then rose by 29.82% to -$6.5 million in 2025.
- Per Business Quant, the three most recent readings for INMB's EBIAT are -$6.5 million (Q3 2025), -$24.5 million (Q2 2025), and -$9.7 million (Q1 2025).